Stereokem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 5.00 Cr
as on 23-10-2024
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.61 Cr
as on 23-10-2024
- Revenue 1010.97%
(FY 2023)
- Profit -255.18%
(FY 2023)
- Ebitda 190.59%
(FY 2023)
- Net Worth 4.13%
(FY 2023)
- Total Assets 38.61%
(FY 2023)
About Stereokem Pharmaceuticals
The Corporate was formerly known as Stereo Kem Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹13.61 Cr.
Venkateshwar Kumar, Thaduri Srivani, and Narayana Vegiraju serve as directors at the Company.
- CIN/LLPIN
U24100AP2012PTC112863
- Company No.
112863
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Stereokem Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkateshwar Kumar  | Director | 11-Feb-2012 | Current |
| Thaduri Srivani | Director | 26-Dec-2012 | Current |
| Narayana Vegiraju | Director | 31-Mar-2022 | Current |
Financial Performance of Stereokem Pharmaceuticals.
Stereokem Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1010.97% increase. The company also saw a substantial fall in profitability, with a 255.18% decrease in profit. The company's net worth moved up by a moderate rise of 4.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stereokem Pharmaceuticals?
In 2023, Stereokem Pharmaceuticals had a promoter holding of 71.40% and a public holding of 28.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stereokem Private LimitedActive 15 years 5 monthsVenkateshwar Kumar and Thaduri Srivani are mutual person
Jyostna Laboratories Private LimitedActive 16 years 2 monthsVenkateshwar Kumar and Thaduri Srivani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Sep 2021 | ₹1.13 M | Open |
Hdfc Bank Limited Creation Date: 24 Mar 2021 | ₹13.50 Cr | Open |
How Many Employees Work at Stereokem Pharmaceuticals?
Stereokem Pharmaceuticals has a workforce of 48 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stereokem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stereokem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
